HerpV
/ Agenus
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 29, 2024
Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond.
(PubMed, Viruses)
- "Notably, several vaccines-SL-V20, HF10, VC2, and mRNA-1608-have shown promising preclinical results, suggesting that an effective HSV vaccine may be within reach. However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections."
Journal • Review • Herpes Simplex • Infectious Disease
July 13, 2021
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
(clinicaltrials.gov)
- P2a; N=80; Completed; Sponsor: Agenus Inc.; Phase classification: P2 ➔ P2a
Clinical • Combination therapy • Phase classification • Herpes Simplex • Infectious Disease • PCR
1 to 2
Of
2
Go to page
1